Ginger Haynes

Eli Lilly and Company

Bio:

Ginger has more than twenty-five years of experience in the pharmaceutical industry, 19 years with Eli Lilly and Company (Lilly). She completed her PhD in statistics at Baylor University and started her career at Lilly in Global Statistics, supporting FDA submissions in schizophrenia, Parkinson's disease, and Alzheimer's disease and subsequently serving as lead US statistician for a launching ADHD compound designing multiple positive phase IIIB/IV studies in that disease state. With i3 Global, Medical and Scientific Affairs, she consulted on research across neuroscience. Ginger rejoined Lilly as a health outcomes research scientist initially designing and executing the health outcomes research strategy for two neuroscience compounds, then serving as a founding member of the Real-World Evidence hub that advanced use of RWE across Lilly. She currently works as a health outcomes scientist in immunology with a specific effort to collaborate across functional and team boundaries to evaluate the use of digital technology to generate holistic real-world evidence. Ginger has extensive experience in various prospective and retrospective observational research methods and enjoys the art of communicating complex topics to cross-functional audiences